NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Agenus Inc. (“Agenus” or “the Company”) (NASDAQ: AGEN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Agenus securitie ...

NEW YORK, Sept. 9, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN) and certain officers. The class action, filed in the United States District Court for the District of Massachusetts, and docketed under 24-cv-12299, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Agenus securities between January 23, 2023 and July 17, 2024, both date ...

NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Agenus Inc. (“Agenus” or the “Company”) (NASDAQ: AGEN) between January 23, 2023 and July 17, 2024, inclusive (the “Class Period”). For more information, submit a form at Agenus Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, o ...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Sept. 09, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN) investors of a class action representing investors that bought securities between January 23, 2023 and July 17, 2024, inclusive (the "Class Period"). Agenus investors have until November 5, 2024 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy ...

ATLANTA, Sept. 09, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Agenus Inc. (“Agenus” or “the Company”) (NASDAQ: AGEN). The lawsuit alleges that Defendants made false and/or misleading statements and/or failed to disclose material information regarding the Company’s business, operations, and prospects, including allegations that: (i) the combination therapy of botensilimab and balstilimab was less effective than Defendants had led investors to believe; and (ii) accordin ...

NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all persons or entities who purchased or otherwise acquired Agenus Inc. (NASDAQ: AGEN) securities between January 23, 2023 and July 17, 2024, inclusive (the “Class Period”). The lawsuit seeks to recover damages for the Company’s investors under the federal securities laws. The Complaint allege ...

临床试验结果 - 公司在约1,100名患者的BOT/BAL临床项目中展示了在10种不同癌症和早期到晚期疾病中的强大活性[5] - 在复发/难治性MSS结直肠癌的随机对照II期试验中,BOT 75mg/BAL组合的客观缓解率为19.4%,6个月总生存率为90%[5] - 在NEST-2队列中,78%的MSS结直肠癌患者实现了至少50%的肿瘤缩小,56%实现了完全病理缓解[6] - BOT/BAL在不同转移部位的结直肠癌中表现一致,客观缓解率为18-33%,疾病控制率为67-82%[6] 临床试验进展 - 公司已与FDA就III期试验的设计和剂量方案达成一致,并计划尽快启动[6] 商业合作 - 公司正在与多家大型生物制药公司就BOT/BAL的全球合作进行讨论[8] 患者支持计划 - 公司推出了BOT/BAL的特殊患者使用计划,为有需要的患者提供早期获取机会[10,11] 财务状况 - 公司2024年第二季度现金余额为9,372.3万美元,经营活动现金流出7,637.1万美元[12,13,14]

研发和临床试验 - 公司正在开发针对癌症的免疫疗法组合疗法，包括抗体治疗、细胞疗法和疫苗佐剂[113][114][115] - 公司已建立从新靶点发现到制药的全面能力,可加快候选药物的开发[114] - 公司的主要项目包括botensilimab和balstilimab,正在进行多项临床试验以支持加速开发[116][117] - MiNK正在扩大其临床项目，包括一项针对二线胃癌的外部资助的II期试验正在积极招募患者，并正在计划一项针对病毒性急性呼吸窘迫综合征(ARDS)的随机对照II期试验[132] - 最近MiNK获得了580万美元的私募融资，将推动其靶向纤维细胞激活蛋白(FAP)的领先同种异体CAR-iNKT细胞疗法MiNK-215的临床开发，计划于2025年初进入临床试验[132] 合作伙伴关系 - 公司与多家公司建立了合作关系,包括百时美施贵宝、贝达药业、UroGen、吉利德、Incyte和默克[118][119][120][122][123][124][125] - 公司的部分策略是通过现有合作伙伴关系和新的合作关系来开发和商业化部分产品候选药物[157] 财务状况 - 研发费用同比下降31%至8070万美元，主要是由于抗体项目相关费用的时间性下降、人员费用减少以及子公司活动费用下降[142,143] - 非经营收益增加620万美元至600万美元,主要是由于确认了550万美元的提前终止两份租赁合同的收益以及在英国确认了研发税收抵免[144] - 利息费用净额增加至6120万美元,主要是由于与HCR的特许权使用费购买协议和与Ligand的购买协议相关的非现金利息费用增加[145] - 公司正在采取措施应对流动性需求，可以灵活调整支出以保持流动性[155] - 公司预计未来资金来源包括现有合作伙伴付款、新的第三方协议、资产出售、特许权使用费变现以及股权证券销售等[155] - 公司未来现金需求包括支持临床试验和监管工作以及持续研发项目[156] - 公司已与多家第三方供应商签订协议,预计未来总支付额为6.634亿美元[156] - 公司未来现金流的产生取决于产品获批上市和市场接受度,以及新的合作关系[158] 子公司发展 - 公司通过子公司SaponiQx推进新型佐剂的开发,特别是培养植物细胞QS-21佐剂[127][128][129][130] - 完成了MiNK的首次公开募股(IPO)，MiNK在纳斯达克资本市场上市交易，股票代码为"INKT"[132]

Agenus (AGEN) came out with a quarterly loss of $2.52 per share versus the Zacks Consensus Estimate of a loss of $1.33. This compares to loss of $4 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -89.47%. A quarter ago, it was expected that this biotechnology company would post a loss of $3.58 per share when it actually produced a loss of $3.04, delivering a surprise of 15.08%.Over the last four quarters, the company has surpa ...

The market expects Agenus (AGEN) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on August 8, 2024, might help the stock move higher if these key numbers are better ...